Unveiling its second asset-centric deal, F-star CEO Dr. John Haurum reveals to Mike Ward, global director of content for Informa's pharma insights products, how the company is looking to raise an additional $30m this year to help the company move some of its own programs into the clinic within 18 months. Dr. Haurum describes differences in the deals involving F-star alpha, an option deal with Bristol-Myers Squibb, and F-star beta which will see AbbVie get access to assets that will allow it to create bispecific antibodies targeting two particular immuno-oncology checkpoints.
This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016. Further panel discussions and...
